Pfiz­er's RSV vac­cine for old­er adults nabs FDA ad­comm rec­om­men­da­tion

FDA’s vac­cine ad­vi­so­ry com­mit­tee gave a thumbs-up to Pfiz­er’s RSV vac­cine on Tues­day, set­ting the stage for GSK’s RSV ad­comm com­ing on Wednes­day.

Af­ter more than sev­en and a half hours of dis­cus­sion and de­lib­er­a­tion, mem­bers of the Vac­cines and Re­lat­ed Bi­o­log­i­cal Prod­ucts Ad­vi­so­ry Com­mit­tee (VRB­PAC) vot­ed 7-4, with 1 ab­sten­tion, that Pfiz­er’s da­ta sup­port safe­ty of its RSV vac­cine can­di­date, which would be brand­ed as Abrys­vo, in adults at least 60 years of age. The com­mit­tee al­so vot­ed the ex­act same way on ef­fi­ca­cy — 7-4 with 1 ab­sten­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER